Search
for
Sort by
Research
540-570 / 1000+ resultsresearch Finasteride
research Approaching fertility in congenital adrenal hyperplasia: exploring P30L mutation-induced 21-hydroxylase deficiency with a presentation between non-classical and simple virilizing phenotypes. A case report
A woman with a specific mutation causing adrenal gland issues faced fertility problems, but careful hormone therapy helped her manage it successfully.
research Depression risk of 5-alpha reductase inhibitors: A systematic review and meta-analysis with a focus on comparator groups
5-alpha reductase inhibitors may increase depression risk by 31%, but results vary based on comparison groups.
research Androgens and acne: perspectives on clascoterone, the first topical androgen receptor antagonist
Clascoterone is a new, effective, and safe acne treatment without systemic side effects.
research Design, synthesis and anti-tumor evaluation of novel thiohydantoin congeners as androgen receptor antagonists with in vivo study.
A new compound, 3a, effectively fights prostate cancer better than finasteride.
research Recent discoveries and developments of androgen receptor based therapy for prostate cancer
New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.
research Cinnamomi Cortex (Cinnamomum verum) Suppresses Testosterone-induced Benign Prostatic Hyperplasia by Regulating 5α-reductase
Cinnamomi cortex may help treat prostate enlargement by reducing related proteins.
research 9209 Functional Evaluation Of Novel CYP21A2 Variants: Expanding The Genetic Basis Of Non-classic CAH
Certain genetic variants impair enzyme activity, contributing to non-classic congenital adrenal hyperplasia.
research Interventions for hirsutism excluding laser and photoepilation therapy alone: abridged Cochrane systematic review includingGRADE assessments
Some medications can reduce excessive hair growth in women, but more research is needed to find the best treatment combinations.
research Slow progress in prostate cancer
Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.
research ISID1343 - Efficacy of asymmetric siRNA targeting androgen receptor for the treatment of androgenetic alopecia
The conclusion is that a treatment called cp-asiAR can reduce hair loss and promote hair growth, making it a potential new therapy for androgenetic alopecia.
research Circumscribed Alopecia Areata Incognita and Response to Tofacitinib
Tofacitinib helped a woman regrow her hair without relapses after other treatments failed.
research Caffeic acid N-[3,5-bis(trifluoromethyl)phenyl] amide as a non-steroidal inhibitor for steroid 5α-reductase type 1 using a human keratinocyte cell-based assay and molecular dynamics
Compound 4 is a promising treatment for hair loss with low toxicity.
research The combination of ethinylestradiol/cyproterone acetate is temporarily withdrawn from the market in France. Is the measure justified?
The paper suggests that France's suspension of Diane-35 was hasty and could cause treatment issues and unintended pregnancies, recommending a re-evaluation and better patient information.
research Preliminary pharmacokinetics and metabolism of novel non-steroidal antiandrogens in the rat: Relation of their systemic activity to the formation of a common metabolite
Two non-steroidal antiandrogens, RU 58841 and RU 56187, form a common metabolite at different rates, which may influence their effects; RU 56187 could be used for prostate cancer treatment and RU 58841 for acne treatment.
research 1048 Treatment of nodulocystic acne with once weekly finasteride: A pilot study
research A population‐based nested case–control study: the use of 5‐alpha‐reductase inhibitors and the increased risk of osteoporosis diagnosis in patients with benign prostate hyperplasia
Taking finasteride for benign prostate hyperplasia may increase the risk of osteoporosis, especially at higher doses.
research Gene-Environment Interaction Between CYP1B1 and Oral Contraception on Frontal Fibrosing Alopecia
Oral contraceptive use may increase the risk of frontal fibrosing alopecia in women with a specific CYP1B1 gene variant.
research Five-alpha-reductase Inhibitors for prostate cancer prevention.
5-alpha-reductase inhibitors can lower prostate cancer risk but may increase high-grade tumors and cause sexual side effects.
research Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study
Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.
research An assessment of (1) cyproterone acetate and (2) ethinyl oestradiol and lynoestrenol (Minilyn) in the treatment of idiopathic hirsutism
Cyproterone acetate can effectively treat idiopathic hirsutism, but ethinyl oestradiol and lynoestrenol may not always reduce hair growth.
research The antiandrogenic effect of finasteride against a mutant androgen receptor
Finasteride may improve prostate cancer treatment outcomes.
research Antiandrogenic progestins for treatment of signs of androgenisation and hormonal contraception
Certain hormone medications can treat symptoms like acne and unwanted hair, regulate periods, and prevent pregnancy in women and teenage girls.
research 5-alpha-reductase inhibitors are associated with reduced frequency of COVID-19 symptoms in males with androgenetic alopecia (vol 35, pg e243, 2021)
Men with hair loss who take a certain type of medication may experience fewer COVID-19 symptoms.
research C19and C215β/5αMetabolite Ratios in Subjects Treated with the 5α-Reductase Inhibitor Finasteride: Comparison of Male Pseudohermaphrodites with Inherited 5α-Reductase Deficiency*
Finasteride may treat baldness but less effective for those with 5α-reductase deficiency.
research CYP21A2 Mutations in Women with Polycystic Ovary Syndrome (PCOS)
Mutations in the CYP21A2 gene are not a major factor in causing PCOS.
research Risk of rhabdomyolysis from 5-α reductase inhibitors
Starting 5-alpha reductase inhibitors does not significantly increase the risk of rhabdomyolysis in older men, but is linked to a higher risk of muscle conditions.
![Discovery of (2S)-N-(6-Cyano-5-(Trifluoromethyl)Pyridin-3-Yl)-3-(6-(4-Cyanophenyl)-3,6-Diazabicyclo[3.1.1]Heptan-3-Yl)-2-Hydroxy-2-Methylpropanamide as a Highly Potent and Selective Topical Androgen Receptor Antagonist for Androgenetic Alopecia Treatment](/images/research/693e7bf6-2325-4ddc-a20f-3470db9f4516/small/25627.jpg)
research Discovery of (2S)-N-(6-Cyano-5-(trifluoromethyl)pyridin-3-yl)-3-(6-(4-cyanophenyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-2-hydroxy-2-methylpropanamide as a Highly Potent and Selective Topical Androgen Receptor Antagonist for Androgenetic Alopecia Treatment
A new topical treatment for hair loss shows strong hair growth effects with low toxicity.
research Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician’s Choice Standard-of-Care Chemotherapy
Talazoparib is more effective than standard chemotherapy for advanced breast cancer with BRCA mutations.